Document Detail


Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
MedLine Citation:
PMID:  20798929     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
INTRODUCTION: The purpose of this study was to evaluate adherence and persistence with teriparatide.
METHODS: Beneficiaries with at least one claim for teriparatide in 2003 or 2004 and continuous enrollment in the previous 12 months and subsequent 6 months were identified in a national commercial/Medicare and Medicaid administrative claims database (MarketScan®). Adherence was assessed through calculation of the medication possession ratio (MPR). Persistence was measured by time until discontinuation and time until first 60-day gap in treatment. Factors associated with persistence were assessed using Cox proportional hazards models.
RESULTS: The average MPR at 6 months was 0.74 (N=2,218) and at 12 months, was 0.66 (N=1,303). At 6 months, 64.6% of patients remained on therapy and at 12 months, 56.7% remained. Bone mineral density screening and use of antiresorptive therapy within the 12 months pre-period, and lower patient copayments were associated with increased persistence.
CONCLUSION: Patients appear to have good adherence with teriparatide over the first 6 months which declines over time. Prior screening and treatment of osteoporosis and out of pocket costs appear to impact persistence. To optimize patient outcomes, clinicians should consider clinical factors that impact persistence, while healthcare decision makers should consider the negative effect of higher patient copayments on persistence.
Authors:
S A Foster; K A Foley; E S Meadows; J A Johnston; S S Wang; G M Pohl; S R Long
Related Documents :
20926319 - Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcin...
19298219 - Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis ...
9637459 - Assessing outcomes, costs, and benefits of emerging technology for minimally invasive s...
17514399 - Health economic evaluation of therapeutic strategies in patients with idiopathic achala...
11147239 - Can practice guidelines be transported effectively to different settings? results from ...
20335789 - Comparison of short-acting intramuscular antipsychotic medication: impact on length of ...
21829969 - Antibiotic treatment schemes for very severe community-acquired pneumonia in children: ...
25130149 - Low-dose human chorionic gonadotropin adjunct to an antagonist protocol in assisted rep...
10448449 - Treatment of neuroleptic-induced akathisia with the 5-ht2 antagonist mianserin. double-...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-27
Journal Detail:
Title:  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA     Volume:  22     ISSN:  1433-2965     ISO Abbreviation:  Osteoporos Int     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100105     Medline TA:  Osteoporos Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  551-7     Citation Subset:  IM    
Affiliation:
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. fostersa@lilly.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polymorphisms in the 5' flank of COL1A1 gene and osteoporosis: meta-analysis of published studies.
Next Document:  Deoxynivalenol: mechanisms of action, human exposure, and toxicological relevance.